Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.

about

Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.

Item

http://www.wikidata.org/entity/Q55152453

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.

@en

Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.

@nl

type

Item

label

Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.

@en

Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.

@nl

prefLabel

Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.

@en

Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.

@nl

P1476

Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.

@en

P2093

Eckart Haneke

http://www.w3.org/2001/XMLSchema#string

P2860

Interventions for nail psoriasis

Nail Psoriasis: A Review of Treatment Options

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis

Single Blinded Left-to-Right Comparison Study of Excimer Laser Versus Pulsed Dye Laser for the Treatment of Nail Psoriasis.

Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study.

Pulsed dye laser in the treatment of nail psoriasis.

Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis.

The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, double-blind, intrapatient left-to-right study.

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.

P304

51-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/PTT.S126281

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29387608

http://www.w3.org/2001/XMLSchema#string

P932

5774607

http://www.w3.org/2001/XMLSchema#string